Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schulz, H
Right arrow Articles by Engert, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schulz, H
Right arrow Articles by Engert, A
Haematologica, Vol 89, Issue 6, 753-754
Copyright © 2004 by Ferrata Storti Foundation

Letter

Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab

H Schulz, H Pels, I Schmidt-Wolf, U Zeelen, U Germing, and A Engert

Most patients with primary central nervous system (CNS) lymphoma or systemic non-Hodgkin's lymphoma (NHL) involving the CNS relapse after an initial response to treatment, often presenting with leptomeningeal disease. Since the majority of these lymphomas are B-cell neoplasms expressing the CD20 surface antigen treatment with the chimeric monoclonal antibody (Mab) rituximab might be a new therapeutic option. Here, we report on 6 patients with relapsed CNS B-cell lymphoma who were treated with intraventricular or intrathecal applications of rituximab. One of these cases has already been reported.


This article has been cited by other articles:


Home page
 JCOHome page
J. Salzburg, B. Burkhardt, M. Zimmermann, O. Wachowski, W. Woessmann, I. Oschlies, W. Klapper, H.-H. Wacker, W.-D. Ludwig, F. Niggli, et al.
Prevalence, Clinical Pattern, and Outcome of CNS Involvement in Childhood and Adolescent Non-Hodgkin's Lymphoma Differ by Non-Hodgkin's Lymphoma Subtype: A Berlin-Frankfurt-Munster Group Report
J. Clin. Oncol., September 1, 2007; 25(25): 3915 - 3922.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. D. Morrey, V. Siddharthan, A. L. Olsen, H. Wang, J. G. Julander, J. O. Hall, H. Li, J. L. Nordstrom, S. Koenig, S. Johnson, et al.
Defining Limits of Treatment with Humanized Neutralizing Monoclonal Antibody for West Nile Virus Neurological Infection in a Hamster Model
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2396 - 2402.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. F. Ferrucci, A. Vanazzi, G. Tesoriere, M. Ferrari, M. Bartolomei, P. Rocca, M. Cremonesi, G. Paganelli, and G. Martinelli
Cerebrospinal fluid diffusion of Zevalin(R) after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement
Ann. Onc., October 1, 2005; 16(10): 1710 - 1711.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.